(RTTNews) - AbbVie (ABBV) reported positive results from the Phase 2 APEX Part B study of zumilokibart, in adults with moderate to severe atopic dermatitis. All three dose regimens met the study's primary endpoint, demonstrating significantly greater EASI-75 response rates compared with placebo at Week 16. Zumilokibart is a half-life extended monoclonal antibody targeting IL-13 and is being developed as a potential treatment for atopic dermatitis. According to the company, the mid-dose regimen was selected for Phase 3 development based on its efficacy, safety and dosing profile. The data are being presented as a late breaker at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.